Results 111 to 120 of about 644,370 (183)

Atrial fibrillation in breast cancer therapy: does tamoxifen confer a lower risk than aromatase inhibitors? [PDF]

Cardiooncology
Kwaah PA, Mensah SA, Agyemang EA, Kekrebesi JS, Katkov D, Carboo A, Appah G, Rashid HA, Kwan JM.   +8 more
europepmc   +1 more source

Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database. [PDF]

Front Pharmacol
Wu YY, Huang QL, Luo ZY, Song XY, Shi YY, Zheng JZ, Liu S.   +6 more
europepmc   +1 more source

Pain sensation and emotion induced by aromatase inhibitors: a new mouse model. [PDF]

Pain
Li H, Han L, Li P, Lu D, Feng Y.
europepmc   +1 more source

Prognostic performance of thymidine kinase 1 activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with CDK4/6 and aromatase inhibitors. [PDF]

Breast Cancer Res Treat
Brown NL, Howell SJ, Papantoniou D, Eriksson O, Bergqvist M, Williams A, Kavanagh A, Backlund A, Albu-Kareem A, Elinder E, Larsson K, Uminska M, Ekholm M.   +12 more
europepmc   +1 more source

Radiogenomic Landscape of Metastatic Endocrine-Positive Breast Cancer Resistant to Aromatase Inhibitors. [PDF]

Cancers (Basel)
Khanyile R, Chipiti T, Hull R, Dlamini Z.   +3 more
europepmc   +1 more source

Real-World Effectiveness and Safety of Ribociclib Plus Aromatase Inhibitors in Patients with HR+/HER2- Metastatic Breast Cancer: A Multicenter Experience from Vietnam. [PDF]

Asian Pac J Cancer Prev
Nguyen HT, Le QV, Phung HT, Nguyen QH, Vu HTM, Truong MC.   +5 more
europepmc   +1 more source

Drug-Induced Liver Injury Secondary to Endocrine Therapy With Aromatase Inhibitors: A Case Report. [PDF]

Cureus
Smith NJ, Watchalotone S, Sandhu S.
europepmc   +1 more source

Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy. [PDF]

Breast
Shai A, Wildiers H, Venieri C, Pogoda K, Linderholm B, Lambertini M, Matos L, De Maio D'Esposito E, Hajjaji N, Matos E, González Cortijo L, Fotia G, Fortuna A, Sella T, Gouveia H, Rosset L, Constantinidou A, Angeli E, Cicin I, Tjan-Heijnen V, Ruyssers N, Demasure S, Abu Remilah A, Huygh G, Paluch-Shimon S, Chiappe E, Shirron N, Neven P, Artac M, Kilictas B, Baranseh J, Vicente-Rubio E, Atci M, Amato O, van Duijnhoven F.   +34 more
europepmc   +1 more source

Efficacy of Dual Hormonal Therapy with Fulvestrant and Aromatase Inhibitors as Neoadjuvant Endocrine Treatment for Locally Advanced Breast Cancer. [PDF]

Cancers (Basel)
Majić A, Bajić Ž, Ban M, Tica Sedlar I, Čerina Pavlinović D, Petrić Miše B, Strikić A, Tomić S, Vrdoljak E.   +8 more
europepmc   +1 more source

Effectiveness of supervised vs brief counselling physical activity promotion interventions in breast cancer survivors on aromatase inhibitors: the PAC-WOMAN randomized controlled trial. [PDF]

Int J Behav Nutr Phys Act
Carraça EV, Rodrigues B, Franco S, Nobre I, Jerónimo F, Ilharco V, Silva PF, Palmeira AL, Silva MN.   +8 more
europepmc   +1 more source